Microcyn Clinical Trials in Mildly Infected Diabetic Foot Ulcers

Oculus Innovative Sciences (NASDAQ: OCLS) has completed a proof-of-concept Phase II trial in the United States, which demonstrated the effectiveness of Microcyn® Technology in mildly infected diabetic foot ulcers with the primary endpoint of clinical cure and improvement of infection. They used 15 clinical sites and enrolled 48 evaluable patients in three arms, using Microcyn® […]